Slide 1: Danaher Corporation Fourth Quarter 2020 Earnings Release
DANAHER CORPORATION Fourth Quarter 2020 Earnings Release January 28, 2021
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding Danaher’s anticipated future financial performance and any other statements regarding events or developments that we anticipate will or may occur in the future are "forward
Slide 3: 2020 Performance Summary: Revenue
2020 Performance Summary: Revenue Q4 REVENUE FY REVENUE +39.0% +24.5% Core including Cytiva +15.5% Core including Cytiva +9.5% Amounts shown are in $ millions. Throughout this presentation, with respect to revenue performance, for the definitions of “Acquisitions,” “Core,” "Core including Cytiva," a
Slide 4: 2020 Performance Summary: Operating Profit Margin
2020 Performance Summary: Operating Profit Margin Q4 OPERATING PROFIT MARGIN FY OPERATING PROFIT MARGIN +390 bps +70 bps Core +360 bps Core +170 bps Acquisitions +60 bps Acquisitions +125 bps Other -30 bps Other -225 bps Throughout this presentation when referred to in connection with operating prof
Slide 5: 2020 Performance Summary: Adjusted Diluted Net EPS
2020 Performance Summary: Adjusted Diluted Net EPS Q4 ADJ. DILUTED NET EPS FY ADJ. DILUTED NET EPS +62.5% +43.0% For the definition of Adjusted Diluted Net EPS, please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "Investors" secti
Slide 6: 2020 Performance Summary: Free Cash Flow Performance
2020 Performance Summary: Free Cash Flow Performance Q4 FREE CASH FLOW FY FREE CASH FLOW +133.5% +79.0% Amounts shown are in $ millions. For the definition of Free Cash Flow, please refer to the accompanying information required by Regulation G, located at the end of this presentation and on the "In
Slide 7: Fourth Quarter 2020: Life Sciences
Fourth Quarter 2020: Life Sciences REVENUE OPERATING PROFIT MARGIN +75.5% +290 bps Core including Cytiva +18.5% Core +330 bps Acquisitions +105 bps Other -145 bps Amounts shown are in $ millions. 7
Slide 8: Fourth Quarter 2020: Diagnostics
Fourth Quarter 2020: Diagnostics REVENUE OPERATING PROFIT MARGIN +23.5% +680 bps Core +21.5% Core +680 bps Acquisitions —% Acquisitions — bps FX +2.0% Other — bps Amounts shown are in $ millions. 8
Slide 9: Fourth Quarter 2020: Environmental & Applied Solutions
Fourth Quarter 2020: Environmental & Applied Solutions REVENUE OPERATING PROFIT MARGIN +2.0% -210 bps Core +1.0% Core -180 bps Acquisitions +0.5% Acquisitions -30 bps FX +0.5% Other — bps Amounts shown are in $ millions. 9
Slide 10: Guidance
GUIDANCE 10
Slide 11: Q&A
Q&A 11
Slide 12: Danaher
DANAHER
Slide 13: Non-GAAP Reconciliations
Non-GAAP Reconciliations Notes to Reconciliation of GAAP to Non-GAAP Financial Measures A Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above): Adjusted Di
Slide 14: Non-GAAP Reconciliations
Non-GAAP Reconciliations Core Sales Growth and Core Sales Growth Including Cytiva % Change Year Ended December 31, 2020 vs. Comparable 2019 Period Total sales growth (GAAP) 24.5% Impact of: Acquisitions/divestitures (18.0%) Currency exchange rates -% Core sales growth (non-GAAP) 6.5% Impact of Cytiv
Slide 15: Non-GAAP Reconciliations
Non-GAAP Reconciliations 15
Slide 16: Non-GAAP Reconciliations: Statement Regarding Non-GAAP Measures
Non-GAAP Reconciliations Statement Regarding Non-GAAP Measures Each of the non-GAAP measures set forth in this file should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP • With respect to adjusted average common stock and common equivalent shares outst